Skip to main content
. 2020 Jul 6;9(7):63. doi: 10.1038/s41389-020-00249-z

Fig. 4. CXCL5 induces neutrophil chemotaxis and activates neutrophils through ERK and P38 signaling pathways.

Fig. 4

a Chemotaxis assay for neutrophils induced by different concentrations of CXCL5 (10 and 100 nM). b Western blot assays for the expression of phosphorylated ERK and P38 in neutrophils treated with CXCL5. c QRT-PCR analyses of the expression of IL-6, IL-8, IL-17, IL-23, TNF-α, TGF-β, MMP9, VEGF, and PD-L1 in neutrophils treated with CXCL5. d Western blot assays for the expression of phosphorylated ERK and P38 in neutrophils treated with TTCM in the presence of CXCL5 neutralizing antibody. e QRT-PCR analyses of the expression of IL-6, IL-8, IL-17, IL-23, TNF-α, TGF-β, MMP9, VEGF, and PD-L1 in neutrophils treated with TTCM in the presence of CXCL5 neutralizing antibody. f, g QRT-PCR analyses of the expression of IL-6, IL-8, IL-17, IL-23, TNF-α, TGF-β, MMP9, VEGF, and PD-L1 in CXCL5-treated neutrophils in the presence or absence of ERK inhibitor PD98059 (f) and p38 inhibitor SB203580 (g).